ClinicalTrials.gg
CompletedNCT03381482ECTAUSOMEUpdated Aug 20, 2025

Ectosomes, New Biomarkers of Tau Pathology?

An observational study in Alzheimer Disease, sponsored by University Hospital, Lille. Completed at 1 site in France. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2025-08-20.

Sponsored by University Hospital, Lille · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
71
Ages
40 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 11 studies in Alzheimer Disease by University Hospital, Lille — 3 open to participants now, 3 under way, 1 of them phase 3. Alzheimer Disease · University Hospital, Lille.

Started
2017
with 1 other
Observational
4 of 11
1 open now
Registered
7th of 11
by date

Among the 11 studies in Alzheimer Disease by University Hospital, Lille, this one is one of 2 that started in 2017, is one of 4 observational ones, and was the 7th registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 932 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

3 of the 11 studies in Alzheimer Disease by University Hospital, Lille are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 644 Alzheimer Disease studies recruiting now, 284 (44%) set no upper age limit and 55 (9%) stop at 75 or younger; 34 take children under 18; 286 take healthy volunteers.

This study: 40 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Alzheimer Disease by University Hospital, Lille, or all of them as a file.
02

Study summary

In Alzheimer's disease (AD), neurofibrillary degeneration (NFD) is characterized by the intraneuronal aggregation of Tau proteins. The pathology progresses through a hierarchical pathway that may be associated with the intercellular transmission of pathology as demonstrated in our rat models. This transmission implies that Tau is actively secreted and may participate to the first steps of Tau pathology spreading. It is demonstrated in cell lines and animal models (rodents and non-human primates) that Tau is secreted not only in free forms but also in extracellular vesicles. If Tau is found in biological fluids before neuronal death it may represent an early marker of the NFD and will also define therapeutically targets. In this context, the aim is now to transfer this knowledge in humans and to decipher the nature of Tau secreted in plasma and cerebrospinal fluids collected from healthy controls to AD patients, and to decipher if the presence of tau inside vesicles is influenced by the pathology.

03

Conditions studied

  • Alzheimer Disease

Browse trials for

Keywords

  • Alzheimer disease
  • Extracellular vesicles
  • Biomarker
  • Tau
  • CSF
  • Plasma
04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects intended to participate in group 1 have to undergo a lumbar puncture for other reasons than a cognitive complaint. They will be identified in the anaesthesiology department among patients who are waiting for scheduled orthopaedic surgery needing spinal anaesthesia. They will have the sample collection done with its specific procedures in the same time.

if a subject is already followed at the MRRC and meets group 1 eligibility criteria, he/she could be asked to participate in the study and thus be enrolled and followed by a MRRC investigator.

Patients intended to participate in groups 2 to 5 will be identified at the MRRC during their scheduled visit with the investigators specialized in neurology/geriatric medicine.

Eligibility criteria

Inclusion Criteria:

  • Subjects able to undergo a lumbar puncture;
  • Subjects who have a partner who will be required for driving back the subject after the lumbar punction for safety reasons (not required for control subjects);
  • Subjects (or the study partner for group 5) capable of and willing to comply with the protocol and to give their written informed consents after having received and understood the subject information. According to the legal protection or the mental capacities of the subject, he/she will be accompanied by him/her legally acceptable representative during this procedure;
  • Blood coagulation testing
  • Subjects registered with the French Social Security, in agreement with the French law on biomedical experimentation.

Group 1: controls

  • absence of cognitive complaint
  • absence of significant cognitive impairment: >27
  • Negative ApoE4 status (ε 4-/ ε 4-) No family history of AD at first degree Group 2: asymptomatic cases with high risk to develop AD
  • absence of cognitive complaint
  • absence of significant cognitive impairment : MMSE>27
  • known ApoE4 status or family history of AD at first degree Group 3: cases with isolated cognitive complaint
  • presence of a cognitive complaint
  • absence of cognitive impairment assessed by MMSE>27 and standard neuropsychological examination (performed \< 1 year) Group 4: prodromal AD according to the 2007 criteria (Dubois et al., 2007)
  • progressive and significant episodic memory impairment >6 months
  • And at least one of the following: medial temporal atrophy of brain MRI / low Ab42 and increased total and phosphorylated Tau protein in the CSF/ bilateral temporoparietal hypometabolism on brain FDG-PET/ positive amyloid brain PET if available
  • exclusion of any differential diagnoses Group 5: Mild to moderate probable AD-type dementia according to the NIA 2011 criteria
  • progressive and significant cognitive decline >6 months
  • amnestic or any other predominant clinical presentation
  • exclusion of any differential diagnoses
  • MMSE between 15 and 26 (inclusive)

Exclusion Criteria:

  • Subjects with dementia caused by a non-neurodegenerative disease, including patients with severe cerebrovascular risk factor load;

Associated Illnesses or conditions:

  • Subjects with other neurodegenerative disease such as fronto-temporal dementia (FTD), Lewy body dementia and Parkinson's disease;
  • Subjects with other serious neurological disorder such as brain tumour, stroke, epilepsy, hydrocephalus and any condition which contraindicates, in the investigator's judgment, entry to the study;
  • Subjects with demyelinating diseases of the peripheral nervous system such as Guillain-Barre Syndrome;

Biological exclusion criteria:

  • Subjects with known active Virus (HCV), Virus (HBV) or (HIV);
  • Subjects with clinical or significant laboratory abnormalities, in the judgment of the investigator;

Others:

  • Subjects with excessive alcohol intake or drug abuse, in the judgment of the investigator;
  • Subjects who have to perform a lumbar puncture;
  • Subjects who, in the opinion of the Investigator, have a risk of non-compliance to the study procedures or who are otherwise not appropriate to include in this clinical trial (for example, being impossible to contact in case of emergency).
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
71 participants (actual)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Controls

    Group 1: the 4ml of CSF collected in the surgery context will be kept for the study, and 6x5ml of blood will be added to the usual samples.

    Diagnostic Test: CSF drawing during spinal anaesthesia · Diagnostic Test: Fasting blood sample

  • Asymptomatic cases with high risk to develop AD

    Group 2: 10ml of CSF and 6x5ml of blood will be collected

    Diagnostic Test: Fasting blood sample · Diagnostic Test: Lumbar puncture

  • Cases with isolated cognitive complaint

    Group 3: 10ml of CSF and 6x5ml of blood will be collected

    Diagnostic Test: Fasting blood sample · Diagnostic Test: Lumbar puncture

  • Prodromal AD

    Group 4: 10ml of CSF and 6x5ml of blood will be collected

    Diagnostic Test: Fasting blood sample · Diagnostic Test: Lumbar puncture

  • Mild to moderate probable AD-type dementia

    Group 5: 10ml of CSF and 6x5ml of blood will be collected

    Diagnostic Test: Fasting blood sample · Diagnostic Test: Lumbar puncture

Interventions

  • Diagnostic testCSF drawing during spinal anaesthesia

    4mL of CSF by lumbar puncture

  • Diagnostic testFasting blood sample

    6x5 mL of fasting blood sample

  • Diagnostic testLumbar puncture

    10 mL of CSF by lumbar puncture

06

What researchers measure

Primary outcomes

  1. Presence of Tau in extracellular vesicles in CSF

    Tau will be measured by ELISA in extracellular vesicles and the presence of Tau in extracellular vesicles will considered positive if the concentration of Tau is superior to the sensitivity threshold of the antibody used.

    Time frame: Baseline

Secondary outcomes

  1. The ratio of free Tau/vesicular Tau for all groups will be assessed with samples obtained during the visit.

    Tau will be measured by ELISA (concentration of Tau in pg/mL) and using the Nanosight technology (% of vesicles containing Tau). Results will be expressed either in percentage or in concentration (ie concentration of free Tau/concentration of vesicular Tau; % of free Tau/% of vesicular Tau).

    Time frame: Baseline

  2. The presence of clusters of the epigenetic markers H3K9me3 in nuclei of peripheral blood mononuclear cells for all groups will be assessed with samples obtained during the visit.

    The H3K9m3 marker will be revealed by immunodetection and revealed by fluorescence. The presence of one cluster of H3K9m3 will be considered as positive. Results will be expressed in % of cells with clusters.

    Time frame: Baseline

07

Study locations

1 site
  • Hôpital Roger Salengro, CHRU
    Lille, France
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2017 to primary completion in Dec 2022, 60 months.

Of 364 non-industry observational studies under Alzheimer Disease, half reached primary completion within 81 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 203. This study's 60 months is below that.

Counting every sponsor, half of 405 studies reached it within 67 months; a quarter within 35 and three quarters within 171.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 18, 2017
First posted
Dec 22, 2017
StartActual
Dec 20, 2017
Primary completionActual
Dec 21, 2022
CompletionActual
Dec 23, 2022
Last update
Aug 20, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03381482
Responsible party
Sponsor
First posted
Dec 22, 2017
Start date
Dec 20, 2017
Primary completion
Dec 21, 2022
Completion
Dec 23, 2022
Last update
Aug 20, 2025

Study contacts

Vincent DERAMECOURT, MD,PhD
principal investigator · University Hospital, Lille

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion